vimarsana.com
Home
Live Updates
Alkermes plc Reports Financial Results for the Fourth Quarte
Alkermes plc Reports Financial Results for the Fourth Quarte
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022
-- Revenues of $1.17 Billion in 2021, GAAP Loss per Share of $0.30 and Diluted Non-GAAP Earnings per Share of $0.78 -- -- Financial Expectations for 2022 and Updated Long-Term Profitability
Related Keywords
United States ,
Massachusetts ,
Athlone ,
Westmeath ,
Ireland ,
Ohio ,
Waltham ,
Dublin ,
Kenilworth ,
American ,
Katie Joyce ,
Iain Brown ,
Catot Laurencin ,
Sandy Coombs ,
Janssen Pharmaceutica ,
American Society Of Clinical Oncology ,
Psych Congress ,
Rodin Therapeutics Inc ,
Neuroscience Education Institute ,
Nasdaq ,
Merck Co Inc ,
Johnson Company ,
Alkermes Inc ,
International Society For Affective Disorders ,
Alkermes ,
Society For Immunotherapy Of Cancer ,
Drug Administration ,
Development Revenues ,
Merck Sharp Dohme Corp ,
Exchange Commission ,
Biogen Ma Inc ,
Alkermes Pharma Ireland ,
Proprietary Products ,
Continued Operating ,
Richard Pops ,
Chief Executive Officer ,
Goods Manufactured ,
Rodin Therapeutics ,
Chief Financial Officer ,
International Society ,
Affective Disorders ,
American Society ,
Clinical Oncology ,
Cancers Symposium ,
Sarissa Capital Management ,
Private Securities Litigation Reform Act ,
Annual Report ,
Alkermes Pharma Ireland Limited ,
Merck Sharp ,
Dohme Corp ,
Additional Information ,
General Meeting ,
Information Regarding Participants ,
Current Reports ,
Initial Statements ,
Beneficial Ownership ,
Financial Information ,
Consolidated Statements ,
Per Share ,
Average Number ,
Ordinary Shares Outstanding ,
Earnings Per Share ,
Calendar Year ,
Net Loss ,
Reports ,
Financial ,
Results ,
Fourth ,
Quarter ,
Ear ,
Nded ,
021 ,
Rovides ,
Expectations ,
022 ,